A Trial to Evaluate the Effect of C21 on Endothelial Dysfunction in Subjects With Type 2 Diabetes
Status:
Recruiting
Trial end date:
2023-07-30
Target enrollment:
Participant gender:
Summary
This trial is a single-centre, randomized, double-blind, placebo-controlled, 2-way cross-over
phase 1b trial evaluating the pharmacodynamic effect of C21 on endothelial dysfunction and
safety in subjects with type 2 diabetes mellitus (T2DM).